Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone

Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study

(2012) Yuejin Chen et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics

(2012) A M Devlin et al.   Translational Psychiatry

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review

(2012) Gavin P. Reynolds   Clinical Psychopharmacology and Neuroscience

Polymorphisms of INSIG2, MC4R, and LEP Are Associated With Obesity- and Metabolic-Related Traits in Schizophrenic Patients

(2011) Po-Hsiu Kuo et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications

(2011) T A P Lett et al.   MOLECULAR PSYCHIATRY

Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting

(2011) Jochem G Gregoor et al.   PHARMACOGENOMICS

Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia

(2011) Chin Cheng et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia

(2010) Sung-Wan Kim et al.   CLINICAL NEUROPHARMACOLOGY

MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study

(2010) Ruud van Winkel et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Association Between the 1291-C/G Polymorphism in the Adrenergic α-2a Receptor and the Metabolic Syndrome

(2010) Arne J. Risselada et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design

(2010) Roberto Coccurello et al.   PHARMACOLOGY & THERAPEUTICS

MTHFR and risk of metabolic syndrome in patients with schizophrenia

(2010) Ruud van Winkel et al.   SCHIZOPHRENIA RESEARCH

Antipsychotic drugs and obesity

(2010) Christoph U. Correll et al.   TRENDS IN MOLECULAR MEDICINE

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

(2009) S. M. Stahl et al.   ACTA PSYCHIATRICA SCANDINAVICA

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study

(2009) Koksal Alptekin et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Association of the α2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European–Americans

(2009) Laertes Sickert et al.   PHARMACOGENOMICS

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study

(2009) Hiroyoshi Takeuchi et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone

(2008) Alessandro Rossi et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

(2008) Vicki L. Ellingrod et al.   SCHIZOPHRENIA RESEARCH